人纤溶酶原kringle 5在大肠杆菌中克隆和分泌表达

构建能够表达分泌性的人纤溶酶原kringle 5（简称hPK-5）的大肠杆菌工程菌。用PCR方法扩增获得hPK-5基因,构建原核表达载体pET-22b（＋）/hPK-5,转化大肠杆菌BL21（DE3）,经IPTG诱导表达并鉴定其免疫学活性。成功表达14kD的重组hPK-5,且约占菌体分泌性蛋白20%以上,经Western Blot分析表明其具有hPK-5的免疫抗原活性。人纤溶酶原kringle 5在大肠杆菌中BL21（DE3）获得可分泌表达。     

双顺反子翻译偶联表达载体的构建及蚓激酶基因F238在大肠杆菌中的可溶性表达

为了实现外源蛋白在大肠杆菌中的可溶性表达,利用硫氧还蛋白作为分子伴侣构建双顺反子翻译偶联表达载体pDICT。将大肠杆菌硫氧还蛋白基因插入到pET22b载体NdeI和EcoR I位点之间,同时在硫氧还蛋白编码基因的终止密码子前加入核糖体结合位点,构建成双顺反子翻译偶联表达载体pDICT。将蚓激酶基因F238克隆到该载体,转化大肠杆菌BL21(DE3)并诱导表达。SDS-PAGE结果表明,所表达的蚓激酶F238是可溶性蛋白。利用血纤维蛋白法对表达产物进行活性测定,重组蚓激酶F238不仅具有纤溶酶活性,而且具有激活纤溶酶原的激酶活性。该双顺反子翻译偶联表达载体的构建,为在大肠杆菌中可溶性表达外源蛋白提供了新方法。     

可溶型三聚体血管生长抑制因子Kringle5的克隆,表达,纯化及活性研究

血管生长抑制因子Kringle 5 是目前发现的抑制血管内皮细胞增殖和肿瘤生长的活性最强的纤溶酶原片段,特异性高而毒副作用小,在肿瘤的治疗方面具有潜在的巨大价值和广阔的应用前景。根据K5基因的序列设计PCR引物,通过PCR从已有的克隆载体扩增出人纤维蛋白溶酶原的K5部分基因,将K5基因克隆入原核表达载体pET15b,经序列测定,成功构建了pET15b-K5非融合表达载体。将重组载体导入大肠杆菌中IPTG诱导表达,SDS-PAGE分析目的蛋白主要以可溶形式存在于菌体中,破碎后上清通过阳离子交换层析,纯化获得纯度大于95%的目标蛋白,脱盐后对分子量测定推测形成了三聚体。通过鸡胚绒毛尿囊膜法证明蛋白产物对鸡胚绒毛尿囊膜血管增生有一定的抑制作用。     

Lys_(10)-PAI-1融合蛋白在大肠杆菌中的表达、纯化和凝胶阻滞实验

用PCR方法构建 10个赖氨酸与纤溶酶原激活剂抑制物 1的融合基因Lys10 PAI 1,并克隆于pET2 8a(+ )和pET32a(+ )原核表达载体 .将重组表达质粒pET32 PAI和pET2 8 PAI转化大肠杆菌BL2 1(DE3) .IPTG诱导后可获得分子量分别为 6 3kD和 4 3kD的目的蛋白 ,表达蛋白占菌体蛋白2 0 %以上 ,大多数重组蛋白以不溶形式存在 .表达产物经变性、复性、超滤、透析和亲和层析等步骤 ,可以得到纯化的Trx·PAI 1和rPAI 1重组蛋白 .Western印迹结果表明 ,目的蛋白具有人PAI 1的抗原性 .凝胶阻滞实验发现 ,纯化的重组蛋白在一定条件下 ,可以与质粒结合 ,使质粒的迁移率明显改变 .研究结果表明 ,Trx·PAI 1和rPAI 1有希望成为受体介导基因转移的配体     

片球菌素pedA基因的原核表达、纯化及生物信息学分析

旨在构建片球菌素PA-1结构基因pedA的原核表达载体,在大肠杆菌体系中实现PA-1的外源表达,运用生物信息学手段分析重组蛋白的理化性质及分子结构。以戊糖片球菌C-2-1的DNA为模板,扩增pedA基因,扩增产物克隆入pET28a(+)原核表达载体,构建pET28a-ped A重组质粒,转入大肠杆菌BL21(DE3)中;30℃,以1 mmol/L IPTG诱导表达5 h;采用Ni-NTA树脂亲和层析纯化重组蛋白,检测纯化后重组蛋白的抑菌活性;利用生物信息学手段探究重组蛋白的理化性质及分子结构信息。结果显示,pET28a-ped A重组质粒构建成功,带有His标签的PA-1重组片球菌素在大肠杆菌中实现了可溶性表达,利用Ni-NTA亲和层析获得纯化的重组蛋白,Tricine-SDS-PAGE电泳分析表明纯化后的重组蛋白分子量约为7.8 k D,与理论值相符。琼脂扩散法抑菌活性实验抑菌圈效果明显,表明纯化的重组片球菌素具有抑菌活性。生物信息学方法对比分析其蛋白结构发现,获得的重组蛋白含有信号肽,α螺旋占23.53%,疏水性提高,可能促进了重组蛋白的可溶性表达。该实验成功构建了片球菌素PA-1的原核表达载体,实现了在大肠杆菌中的可溶性表达,该表达可能与其含有信号肽及信号肽疏水性有关,纯化后的重组蛋白抑菌活性明显。     

重组蛋白ES-Kringle5的表达、纯化及活性检测

目的：利用基因工程方法原核表达重组融合蛋白ES-Kringle5并进行纯化及活性检测。方法：ES-Kringle5是将内皮抑素N端的前27个氨基酸与Kringle5通过连接肽相连的重组融合蛋白,合成该重组蛋白的基因片段并插入载体pMD18-T中,然后克隆至大肠杆菌表达载体pET25b中并转化E.coli BL21（DE3）。乳糖诱导表达后经Ni-NTA亲和层析纯化后获得目的蛋白。通过抑制HUVEC细胞增殖实验检测其生物学活性。结果：重组质粒构建正确。利用乳糖诱导表达并降低诱导温度能增加目的蛋白的产量及可溶性表达。纯化后的重组蛋白纯度大于95%。生物学活性证明该重组蛋白具有抑制HUVEC的增殖能力。结论：具有生物学活性的重组蛋白ES-Kringle5可在大肠杆菌中高效表达,为研究其体内药效、药代及安全性评价奠定了基础。     

重组酶Exo、Beta和Gam在大肠杆菌中的表达与纯化

目的:构建exo、beta和gam基因的原核表达质粒,在大肠杆菌中表达、制备重组酶Exo、Beta和Gam。方法:将exo、beta和gam基因分别构建在原核表达载体pEGKG和pET28a上,分别转化大肠杆菌BL21(DE3)和DH5α,经IPTG诱导后,在大肠杆菌中获得可溶性表达蛋白,用柱层析方法纯化蛋白。结果:构建了原核表达质粒pET28a-exo、pET28a-beta、pET28a-gam和pEGKG-exo、pEGKG-beta、pEGKG-gam;SDS-PAGE结果表明重组酶融合蛋白His-Exo、GST-Exo、His-Beta、GST-Beta、His-Gam、GST-Gam得到可溶性表达;用His标签抗体和GST标签抗体通过Western印迹方法检测到纯化后的融合蛋白。结论:在大肠杆菌中诱导表达了λ噬菌体重组酶,并纯化获得了一定量的纯度较好的蛋白,为下一步制备检测用多克隆抗体奠定了基础。     

非典型性肺炎病毒S蛋白受体结合域的可溶性表达

试验目的是获得S蛋白受体结合域基因,并获得其高效表达,为SARS病毒受体的进一步研究奠定一定的基础。首先通过P（取方法获得了S蛋白起始密码和SalⅠ限制性内切酶之间包含受体结合区的片段,然后将该基因定向克隆到pET-22b原核表达载体,构建了per—22b—S1重组质粒,转化大肠杆菌并诱导目的蛋白的表达,经SDS—PAGE没有发现明显的目的蛋白带。利用载体和S1基因上的NeoⅠ酶切位点,将S1基因的信号肽序列和部分疏水序列切掉后,构建pET—22b—SNS重组质粒。pET—22b—SNS重组质粒仍然包含受体结合域序列,并且阅读框没有改变。将pET—22b—SNS转化大肠杆菌,发现明显的目的蛋白带。Westem blot结果表明表达蛋白为SARS病毒S1蛋白的一部分。     

结核分枝杆菌Rv3369基因的表达和纯化

在大肠杆菌中高效表达结核分枝杆菌Rv3369蛋白,获得纯化的重组蛋白rRv3369。通过聚合酶链反应(Polymerase chain reaction,PCR)扩增Rv3369基因;以质粒pET28a为表达载体,构建重组质粒,转化大肠杆菌BL21(DE3);以异丙基硫代半乳糖苷(IPTG)诱导表达目的蛋白,通过SDS-PAGE鉴定rRv3369在大肠杆菌中的表达,确定rRv3369在大肠杆菌中的表达形式;采用Ni-NTA His.Bind Resin来纯化重组蛋白。重组质粒pET28a-Rv3369中目的基因测序结果与报道序列相同。分子量约19.5kDa,表达量约占菌体总蛋白的18%,纯化后的重组蛋白样品经SDS-PAGE和激光密度扫描分析表明其纯度为90%以上,每100mL培养菌可获得1.56mg左右的重组蛋白。用亲和层析法纯化的重组蛋白纯度较好。     

鲎血细胞中脂多糖结合蛋白TALF在大肠杆菌中的表达研究

TALF(Tachyleus antilipoposaccharide factor)对细菌内毒素（LPS）的核心部分有抑制作用。研究TALF cDNA基因在大肠杆菌中的表达,首先将TALF cDNA基因分别插入大肠杆菌表达载体pGEX-4T-2、pET22b、pET28a中,构建重组表达质粒,转化于大肠杆菌BL21(DE3)。结果表明克隆于pET22b、pET28a中的TALF cDNA基因没有表达,而融合了GST的TALF基因（GST-TALF）能够在大肠杆菌中表达,并形成包涵体。从1L培养基中可获得4mg纯度为91%的GST-TALF融合蛋白。经复性和纯化后的融合蛋白GST-TALF几乎检测不到抑菌活性及LPS中和活性,但该融合蛋白经凝血酶消化后表现出明显的体外抑菌活性及LPS中和活性。     

Metabolism to methionine and growth stimulation by 5'-methylthioadenosine and 5'-methylthioinosine in mammalian cells

Viable human and murine lymphoblasts, and normal human tissue extracts, converted the thioether nucleosides 5'-methylthioadenosine (MeSAdo) and 5'-methylthioinosine (MeSIno) to methionine. Both MeSAdo and MeSIno, but not homocysteine, supported the short-term growth of human or murine lymphoblasts in methionine deficient medium. However, MeSAdo at concentrations greater than 25 microM inhibited cell growth. MeSIno was non-toxic at concentrations up to 200 microM, and supported the long-term growth of lymphoblasts in methionine-free medium.     

Rab5a研究进展

Rab5a是Rab蛋白家族成员之一,属于小GTP酶。Rab5a是早期胞吞途径中一个重要的限速成分,主要负责调控胞吞中胞吞泡与早期内体的融合。近年来国内外对其研究非常活跃。现对Rab5a的结构、相互作用蛋白及功能的最新研究进展进行综述。     

5-HT2和5-HT3受体在外周初级感觉神经末梢痛反应和痛调制中的相互作用

目的：探讨5-HT2和5-HT3受体亚型在5-HT引起外周痛反应和痛调制中的相互作用及其机制;方法：在大鼠三又神经节神经元标本上应用全细胞膜片钳技术记录5-羟色胺激活电流（15_HT）,并结合痛行为实验进行观察。结果：在大多数受检细胞（54／88,61．4％）特别是中、小型细胞外加5-HT可引起一快去敏感的内向电流,此内向电流能被5-HT,受体特异性激动剂2-甲基-5-羟色胺所模拟,被5-HT3受体拮抗剂ICS250-930可逆性阻断,而5-HT2受体激动剂α-甲基-5-羟色胺则有明显增强15-HT的作用,5-HT1受体激动剂R-（＋）-UH301无明显反应。在进一步的整体清醒动物的行为学试验中我们观察到,大鼠后肢掌底皮下注射5-HT（10-5,10-4和10-3mol／L）引起浓度依赖性的痛行为反应,而用5-HT2和5-HT3受体特异性拮抗剂Cyproheptadine和ICS250-930分别阻断相应受体亚型后,5-HT引起的痛行为反应的强度序列为：5-HT〉5-HT＋ICS〉5-HT＋Cyp。结论：本文结果提示：5-HT所引起的痛反应中,在初级感觉神经元水平5-HT3受体可能仅起着启始作用,而5-HT,受体则在伤害性信息的维持和调制过程中发挥更大的作用。     

Non-redundant function of the MEK5-ERK5 pathway in thymocyte apoptosis

The mitogen-activated protein kinases (MAPKs) ERK1/2, p38, and JNK are thought to determine survival-versus-death fate in developing thymocytes. However, this view was challenged by studies using 'MEK1-ERK1/2-specific' pharmacological inhibitors, which block both positive and negative selection. Recently, these inhibitors were also shown to affect MEK5, an upstream activator of ERK5, another class of MAPK with homology to ERK1/2. To define the contribution of the MEK5-ERK5 pathway in T-cell development, we retrovirally expressed dominant-negative or constitutively activated form of MEK5 to inhibit or activate the MEK5-ERK5 pathway. We demonstrate that MEK5 regulates apoptosis of developing thymocytes but has no function in positive selection. ERK5 activity correlates with the levels of Nur77 family members but not that of Bim, two effector pathways of thymocyte apoptosis. These results illustrate the critical involvement of the MEK5-ERK5 pathway in thymocyte development distinct from that of ERK1/2 and highlight the importance of the MAPK network in mediating differential effects pertaining to T-cell differentiation and apoptosis.     

Evidence that intracellular synthesis of 5-fluorouridine-5'-phosphate from 5-fluorouracil and 5-fluorouridine is compartmentalized

L1210 cells were exposed to equitoxic concentrations of [14C]5-fluorouracil and [3H]5-fluorouridine for 4 hours. The RNA from these cells was separated into cytosolic and nuclear fractions, and then further fractionated by chromatography on poly-U Sepharose, Sephadex G-200 and DEAE-cellulose. The ratio of tritium to carbon-14 incorporated into various species of RNA differed by as much as 6-fold, indicating that the respective 5-fluorouridine-5'-monophosphates synthesized from the two precursors are localized in separate pools that do not mix rapidly.     

Regulation of MUC5AC mucin secretion by depletion of AQP5 in SPC-A1 cells

Airway mucus is regulated by many inflammatory mediators such as ILs, TNF-alpha, EGF, PGF2alpha, LT, and so on. Recently, the relationship between membrane ion channel and mucus production has been under investigation. The present study aimed to examine whether AQP5 was involved in modulation of mucin expression and secretion in airway submucosal gland cells (SPC-A1). A recombinant plasmid (pShAQP5) containing small hairpin RNA expression cassette targeting AQP5 sequence was constructed. In pShAQP5 transiently transfected cells, ELISA showed MUC5AC synthesis and secretion were increased by 57.9% and 85.3%, respectively, on day 5 after pShAQP5 transfection. While in five stably transfected clones (shAQP5-G1, G2, G3, A2, and A5), the upregulated levels of MUC5AC mRNA were 118%, 165%, 65%, 123%, and 38%, respectively. The elevated levels of MUC5AC synthesis and secretion varied from 59-156% and 33-166%, respectively. This is the first reliable investigation of the regulation of MUC5AC mucin secretion by silencing AQP5. Further study of the regulatory mechanism between AQPs and mucins may provide new strategies for development of novel antihypersecretory drugs in airway diseases.     

Antisera Against the Indolealkylamines: Tryptophan, 5-Hydroxytryptophan, 5-Hydroxytryptamine, 5-Methoxytryptophan, and 5-Methoxytryptamine Tested by an Enzyme-Linked Immunosorbent Assay Method

Antisera were raised against tryptophan, 5-hydroxytryptophan, 5-hydroxytryptamine, 5-methoxytryptophan, and 5-methoxytryptamine, by conjugating each molecule to bovine serum albumin and to human serum albumin via glutaraldehyde, in such a way as to preserve the original part. Antibody specificity was tested with the enzyme-linked immunosorbent assay method. The specificity of each anti-indolealkylamine-glutaraldehyde antibody was established with competition experiments by using an adsorbed immunogenic conjugate and indolealkylamines either free or conjugated with poly-L-lysine. The nonconjugated compounds were poorly recognized. In the same way, the nonreduced conjugates always appeared less immunoreactive than the reduced ones. Calculated from the specificity study of each antiserum, the cross-reactivity ratios were found to be smallest for the most immunoreactive conjugates. Thus, a specific immune response was defined for each compound belonging to the same metabolic pathway.